Medtronic is rallying today, driven by positive investor sentiment surrounding the company's strategic growth initiatives, including new product codes, recent regulatory approvals, and the ongoing split-off of its diabetes business. While BTIG Research maintained a buy rating on the stock, the firm slightly adjusted its price target downward from $100.00 to $99.00. Additionally, the company announced preliminary results regarding its exchange offer for MiniMed Group, Inc. shares, further contributing to the stock's momentum as it outperforms its peers in the medical device industry.